Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features

Arthritis and Rheumatism

Volumn 63, Issue 8, 2011, Pages 2396-2406

  Crowe, Sherry R ^a,d   Merrill, Joan T ^a,d   Vista, Evan S ^a,d   Dedeke, Amy B ^a,d   Thompson, David M ^b   Stewart, Scott ^a,d   Guthridge, Joel M ^a,d   Niewold, Timothy B ^c   Franek, Beverly S ^c   Air, Gillian M ^b   Thompson, Linda F ^a   James, Judith A ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d St Luke's Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; INFLUENZA VACCINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AFRICAN AMERICAN; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADULT; AUTOANTIBODIES; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; VACCINATION;

EID: 79961119563     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30388     Document Type: Article

References (49)

1. Fessler BJ,. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002; 16: 281-91.
2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999; 78: 167-75. (Pubitemid 29231143)
3. Colonna L, Dinnall JA, Shivers DK, Frisoni L, Caricchio R, Gallucci S,. Abnormal costimulatory phenotype and function of dendritic cells before and after the onset of severe murine lupus. Arthritis Res Ther 2006; 8: R49.
4. Tsokos GC, Liossis SN,. Immune cell signaling defects in lupus: activation, anergy and death. Immunol Today 1999; 20: 119-24. (Pubitemid 29130340)
5. Via CS, Tsokos GC, Bermas B, Clerici M, Shearer GM,. T cell-antigen-presenting cell interactions in human systemic lupus erythematosus: evidence for heterogeneous expression of multiple defects. J Immunol 1993; 151: 3914-22. (Pubitemid 23282703)
6. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-40. (Pubitemid 39223224)
7. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-86. (Pubitemid 36068705)
8. Abu-Shakra M, Press J, Buskila D, Sukenik S,. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenicity issues. Autoimmun Rev 2007; 6: 543-6. (Pubitemid 47374614)
9. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41: 1828-34. (Pubitemid 28465537)
10. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34: 147-53. (Pubitemid 34028344)
11. Brodman R, Gilfillan R, Glass D, Schur PH,. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 1978; 88: 735-40. (Pubitemid 8351371)
12. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R,. Influenza immunization in systemic lupus erythematosus: a double-blind trial. Ann Intern Med 1978; 88: 729-34. (Pubitemid 8351370)
13. Louie JS, Nies KM, Shoji KT, Fraback RC, Abrass C, Border W, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978; 88: 790-2.
14. Ristow SC, Douglas RG Jr, Condemi JJ,. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978; 88: 786-9. (Pubitemid 8351380)
15. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 913-8.
16. Mercado U, Acosta H, Avendano L,. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin 2004; 56: 16-20. (Pubitemid 38559467)
17. Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29: 2555-7. (Pubitemid 35416961)
18. Del Porto F, Lagana B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis: safety and immunogenicity. Vaccine 2006; 24: 3217-23.
19. Abu-Shakra M, Press J, Sukenik S, Buskila D,. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 2002; 21: 369-72.
20. Toplak N, Kveder T, Trampus-Bakija A, Subelj V, Cucnik S, Avcin T,. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev 2008; 8: 134-8.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
22. Malik S, Bruner GR, Williams-Weese C, Feo L, Scofield RH, Reichlin M, et al. Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus 2007; 16: 863-6. (Pubitemid 350157271)
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
24. Petri M,. Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis 2007; 66 Suppl III: iii61-4. (Pubitemid 350032637)
25. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-8. (Pubitemid 41785892)
26. Feng J, Gulati U, Zhang X, Keitel WA, Thompson DM, James JA, et al. Antibody quantity versus quality after influenza vaccination. Vaccine 2009; 27: 6358-62.
27. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453: 667-71. (Pubitemid 351769295)
28. Gulati U, Kumari K, Wu W, Keitel WA, Air GM,. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine 2005; 23: 1414-25. (Pubitemid 40127335)
29. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33. (Pubitemid 37255038)
30. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007; 56: 2344-51. (Pubitemid 47173582)
31. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA,. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005; 11: 85-9. (Pubitemid 40215842)
32. Bruner BF, Wynn DM, Reichlin M, Harley JB, James JA,. Humoral antigenic targets of the ribosomal P0 lupus autoantigen are not limited to the carboxyl region. Ann N Y Acad Sci 2005; 1051: 390-403. (Pubitemid 41362769)
33. Harris EN, Hughes GR, Gharavi AE,. Anti-cardiolipin antibodies and the lupus anticoagulant. Clin Exp Rheumatol 1986; 4: 187-90. (Pubitemid 16056610)
34. McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1226-32. (Pubitemid 38480833)
35. Hua J, Kirou K, Lee C, Crow MK,. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-16. (Pubitemid 43877940)
36. Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK,. Age- and sex-related patterns of serum interferon-α activity in lupus families. Arthritis Rheum 2008; 58: 2113-9. (Pubitemid 351988103)
37. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK,. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492-502. (Pubitemid 47365615)
38. Gulati U, Keitel WA, Air GM,. Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination. Influenza Other Respi Viruses 2007; 1: 147-56.
39. Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2438-47.
40. Abu-Shakra M, Shoenfeld Y,. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001; 10: 152-3. (Pubitemid 32410069)
41. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D,. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 2000; 27: 1681-5. (Pubitemid 30462811)
42. Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford) 2009; 48: 1294-9.
43. Holvast B, Huckriede A, Kallenberg CG, Bijl M,. Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun Rev 2007; 6: 300-5. (Pubitemid 46507990)
44. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L,. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004; 190: 1962-9. (Pubitemid 39564702)
45. Gardner EM, Gonzalez EW, Nogusa S, Murasko DM,. Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population. Vaccine 2006; 24: 1609-14. (Pubitemid 43238237)
46. Stojanovich L,. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 2006; 13: 373-5. (Pubitemid 44950054)
47. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5. (Pubitemid 36297546)
48. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK,. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-503. (Pubitemid 40663941)
49. Blazevic V, Trubey CM, Shearer GM,. Comparison of in vitro immunostimulatory potential of live and inactivated influenza viruses. Hum Immunol 2000; 61: 845-9.